Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Fontana RJ, Brown RS Jr, Moreno-Zamora A, Prieto M, Joshi S, Londoño MC, Herzer K, Chacko KR, Stauber RE, Knop V, Jafri SM, Castells L, Ferenci P, Torti C, Durand CM, Loiacono L, Lionetti R, Bahirwani R, Weiland O, Mubarak A, ElSharkawy AM, Stadler B, Montalbano M, Berg C, Pellicelli AM, Stenmark S, Vekeman F, Ionescu-Ittu R, Emond B, Reddy KR. Fontana RJ, et al. Among authors: stauber re. Liver Transpl. 2016 Apr;22(4):446-58. doi: 10.1002/lt.24416. Liver Transpl. 2016. PMID: 26890629 Free article.
Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. Austrian Hepatitis Study Group.
Ferenci P, Stauber R, Steindl-Munda P, Gschwantler M, Fickert P, Datz C, Müller C, Hackl F, Rainer W, Watkins-Riedel T, Lin W, Krejs GJ, Gangl A; Austrian Hepatitis Study Group. Ferenci P, et al. Eur J Gastroenterol Hepatol. 2001 Jun;13(6):699-705. doi: 10.1097/00042737-200106000-00014. Eur J Gastroenterol Hepatol. 2001. PMID: 11434597 Clinical Trial.
Combination of interferon induction therapy and ribavirin in chronic hepatitis C.
Ferenci P, Brunner H, Nachbaur K, Datz C, Gschwantler M, Hofer H, Stauber R, Hackl F, Jessner W, Rosenbeiger M, Munda-Steindl P, Hegenbarth K, Gangl A, Vogel W; Australian Hepatitis Study Group. Ferenci P, et al. Hepatology. 2001 Nov;34(5):1006-11. doi: 10.1053/jhep.2001.28706. Hepatology. 2001. PMID: 11679972 Clinical Trial.
Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy.
Steindl-Munda P, Ferenci P, Brunner H, Nachbaur K, Datz C, Gschwantler M, Hofer H, Stauber R, Hackl F, Jessner W, Rosenbeiger M, Gangl A, Vogel W; Austrian Hepatitis Study Group. Steindl-Munda P, et al. Liver Int. 2003 Aug;23(4):269-75. doi: 10.1034/j.1600-0676.2003.00838.x. Liver Int. 2003. PMID: 12895267 Clinical Trial.
Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
Ferenci P, Formann E, Laferl H, Gschwantler M, Hackl F, Brunner H, Hubmann R, Datz C, Stauber R, Steindl-Munda P, Kessler HH, Klingler A, Gangl A; Austrian Hepatitis Study Group. Ferenci P, et al. J Hepatol. 2006 Feb;44(2):275-82. doi: 10.1016/j.jhep.2005.09.015. Epub 2005 Nov 7. J Hepatol. 2006. PMID: 16338019 Clinical Trial.
267 results